Revvity Popped On Earnings Boost—Will Feb. 2 Spark The Next Big Move?

Revvity shares surged over 9% after the health-sciences company raised its 2025 earnings per share outlook above $5.00 and boosted Q4 revenue guidance to $772 million, exceeding Wall Street expectations. The company’s preliminary results, released ahead of its presentation at the JPMorgan Healthcare Conference, came as a surprise to a market that had seen RVTY down 9% over the past 12 months. Yet, despite the better-than-expected guidance and a solid 2026 margin outlook, investor sentiment remains cautious. As of mid-January, analysts are almost evenly split: 48% rate RVTY a Buy, while another 48% say Hold. The average price target sits at $112.31, reflecting only modest upside from current levels. The upcoming February 2 earnings report could become a decisive moment—particularly if management’s guidance for 2026 shows acceleration in end-market demand, improvement in China, and margin leverage. Until then, the stock sits at a pivotal juncture, balancing near-term momentum with lingering skepticism.